Ischemia-modified albumin may be a novel marker for the diagnosis and follow-up of necrotizing enterocolitis

Journal of Clinical Laboratory Analysis

Volumn 28, Issue 3, 2014, Pages 170-177

  Yakut, Ibrahim ^a   Tayman, Cüneyt ^b   Oztekin, Osman ^b   Namuslu, Mehmet ^c   Karaca, Fahri ^b   Kosus, Aydin ^c  

^a Oncology Research and Training Hospital   (Turkey)

^b Department of Neonatology Denizli TC Public Health Hospital   (Turkey)

^c TURGUT OZAL UNIVERSITY   (Turkey)

Author keywords

Diagnosis; Ischemia modified albumin; Necrotizing enterocolitis; Newborn; Preterm

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; ISCHEMIA MODIFIED ALBUMIN; BIOLOGICAL MARKER; ISCHEMIA-MODIFIED ALBUMIN; SERUM ALBUMIN;

AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; INFANT; INTESTINE PERFORATION; NECROTIZING ENTEROCOLITIS; PREMATURITY; BLOOD; ENTEROCOLITIS, NECROTIZING; EVALUATION STUDY; METABOLISM; NEWBORN; STATISTICAL MODEL;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENTEROCOLITIS, NECROTIZING; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTERLEUKIN-6; LOGISTIC MODELS; SERUM ALBUMIN;

EID: 84899620358     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21661     Document Type: Article

References (28)

1. Josef N, Walker WA. Necrotizing enterocolitis. N Engl J Med 2011;364:255-264.
2. Lin PW, Nasr TR, Stoll BJ. Necrotizing enterocolitis: Recent scientific advances in pathophysiology and prevention. Semin Perinatol 2008;32:70-82.
3. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: Pathogenesis, prevention and management. Drugs 2008;68:1227-1238.
4. Schnabl KL, Van Aerde JE, Thomson AB, Clandinin MT. Necrotizing enterocolitis: A multifactorial disease with no cure. World J Gastroenterol 2008;14:2142-2161.
5. Kosloske AM. Epidemiology of necrotizing enterocolitis. Acta Paediatr Suppl 1994;396:2-7.
6. Carter BM. Treatment outcomes of necrotizing enterocolitis for preterm infants. J Obstet Gynecol Neonatal Nurs 2007;36:377-384.
7. Schulzke SM, Deshpande GC, Patole SK. Neurodevelopmental outcomes of very low-birth-weight infants with necrotizing enterocolitis: A systematic review of observational studies. Arch Pediatr Adolesc Med 2007;161:583-590.
8. Young C, Sharma R, Handfield M, Mai V, Neu J. Biomarkers for infants at risk for necrotizing enterocolitis: Clues to prevention? Pediatr Res 2009;65:91-97.
9. Tayman C, Tonbul A, Kahveci H, et al. C5a, a complement activation product, is a useful marker in predicting the severity of necrotizing enterocolitis. Tohoku J Exp Med 2011;224:143-150.
10. Sadler PJ, Tucker A, Viles JH. Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins. Comparison with Co2+, Cd2+ and Al3+. Eur J Biochem 1994;220:193-200.
11. Gaze DC. Ischemia modified albumin: A novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 2009;24:333-341.
12. Gunduz A, Turedi S, Mentese A, et al. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008;26:874-878.
13. Gunduz A, Turkmen S, Turedi S, et al. Time-dependent variations in ischemia-modified albumin levels in mesenteric ischemia. Acad Emerg Med 2009;16:539-543.
14. Dundar ZD, Cander B, Gul M, Karabulut KU, Girisgin S. Serum ischemia-modified albumin levels in an experimental acute mesenteric ischemia model. Acad Emerg Med 2010;17:1233-1238.
15. Kumral A, Okyay E, Guclu S, et al. Cord blood ischemia-modified albumin: Is it associated with abnormal Doppler findings in complicated pregnancies and predictive of perinatal asphyxia? J Obstet Gynaecol Res 2013;39:663-671.
16. Gugliucci A, Hermo R, Monroy C, Numaguchi M, Kimura S. Ischemia-modified albumin levels in cord blood: A case-control study in uncomplicated and complicated deliveries. Clin Chim Acta 2005;362:155-160.
17. Walsh MC, Kliegman RM. Necrotizing enterocolitis: Treatment based on staging criteria. Pediatr Clin North Am 1986;33:179-201.
18. Shen XL, Lin CJ, Han LL, Lin L, Pan L, Pu XD. Assessment of ischemia-modified albumin levels for emergency room diagnosis of acute coronary syndrome. Int J Cardiol 2011;149:296-298.
19. Immanuel S, Sanjaya AI. Albumin cobalt binding (ACB) test: Its role as a novel marker of acute coronary syndrome. Acta Med Indones 2006;38:92-96.
20. Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers 2010;15:655-662.
21. Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V. Ischemia modified albumin: Is this marker of ischemia ready for prime time use? Hellenic J Cardiol 2008;49:260-266.
22. Nankervis CA, Giannone PJ, Reber KM. The neonatal intestinal vasculature: Contributing factors to necrotizing enterocolitis. Semin Perinatol 2008;32:83-91.
23. Hunter CJ, Upperman JS, Ford HR, Camerini V. Understanding the susceptibility of the premature infant to necrotizing enterocolitis (NEC). Pediatr Res 2008;63:117-123.
24. Patole S. Prevention and treatment of necrotising enterocolitis in preterm neonates. Early Hum Dev 2007;83:635-642.
25. Claud EC, Walker WA. Hypothesis: Inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis. FASEB J 2001;15:1398-1403.
26. Marshall JC, Vincent JL, Fink MP, et al. Measures, markers, and mediators: Toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003;31:1560-1567.
27. Towfigh S, Heisler T, Rigberg DA, et al. Intestinal ischemia and the gut-liver axis: An in vitro model. J Surg Res 2000;88:160-164.
28. Pourcyrous M, Korones SB, Yang W, Boulden TF, Bada HS. C-reactive protein in the diagnosis, management, and prognosis of neonatal necrotizing enterocolitis. Pediatrics 2005;116:1064-1069.